1521 Article Views
Publication Date: 11 May 2010
Journal: Clinical Medicine Insights: Therapeutics
doi: 10.4137/CMT.S3865
Azelastine HCl (Astelin™) is an intranasal antihistamine indicated for use in patients with seasonal allergic rhinitis (SAR) and non-allergic vasomotor rhinitis (VMR). A side effect of this medication is bitter taste which many patients find aversive. To address the issue of bitter taste, azelastine has been reformulated to include sucralose and sorbitol. The new formulation (Astepro™ 0.1%) is approved for seasonal and perennial allergic rhinitis and has been demonstrated to have comparable pharmacokinetics, pharmacodynamics and therapeutic efficacy compared to Astelin. More recently, Astepro at a concentration 0.15% has been approved for once a day use. This review will provide an overview of the old and new formulations of Azelastine.
Discussion
No comments yet...Be the first to comment.
I highly recommend publication in Libertas Academia journals. The entire submission, review and publication process for our article in Clinical Medicine Insights: Dermatology was easy and quick. The reviews were very professional and helpful and the publication fees were reasonable. We also appreciate that our article is available online free of charge to anyone interested in it.Dr Lisa Roche (New Jersey Department of Health and Senior Services, Trenton, NJ, USA) What our authors say
Copyright © 2011 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)